The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 6, 2004, Pages 679-685

  Norgard B ^a,c   Pedersen, L ^a   Jacobsen, J ^a   Rasmussen, S N ^b   Sorensen H T ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; FELODIPINE; FUROSEMIDE; HYDROCORTISONE; MERCAPTOPURINE; METOPROLOL; OMEPRAZOLE; PREDNISONE;

ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONCEPTION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DENMARK; DRUG SAFETY; FATHER; FEMALE; GLOMERULONEPHRITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SKIN DISEASE;

6-MERCAPTOPURINE; ABNORMALITIES, DRUG-INDUCED; AZATHIOPRINE; COHORT STUDIES; DENMARK; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; MALE; PATERNAL EXPOSURE; RISK FACTORS;

EID: 1842429713     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01889.x     Document Type: Article

References (22)

1. Lamers CB, Griffloen G, van Hogezand RA, Veenendaal RA. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 111-5.
2. Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973; 115: 1100-6.
3. Armenti VT, Moritz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Drug Saf 1998; 19: 219-32.
4. Meuwissen SG, Ewe K, Gassull MA, et al. IOIBD questionnaire on the clinical use of azathioprine, mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000; 12: 13-8.
5. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17.
6. Rajapakse RO, Korelitz BI, Zlatanic J, Baiocco PJ, Gleim GW. Outcome of pregnancies when fathers are treated with mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000; 95: 684-8.
7. Ben Neriah Z, Ackerman Z. WAGR syndrome in a baby - the result of 6-MP treatment in a father affected by Crohn's disease? Am J Gastroenterol 2001; 96: 251.
8. Kane SV. What's good for the goose should be good for the gander - 6-MP use in fathers with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 581-2.
9. Korelitz BI, Rajapakse RO, Zlatanic J, Baiocco PJ, Gleim GW. 6MP for fathers with IBD at the time of conception: the value of a large clinical experience over unrelated controls. Am J Gastroenterol 2000; 95: 2386-7.
10. Katz JA, Pore G. Inflammatory bowel disease and pregnancy. Inflamm Bowel Dis 2001; 7: 146-57.
11. Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf 1999; 21: 311-23.
12. Joffe JM. Influence of drug exposure of the father on perinatal outcome. Clin Perinatol 1979; 6: 21-36.
13. Joffe JM, Soyka LF. Paternal drug exposure: effects on reproduction and progeny. Semin Perinatol 1982; 6: 116-24.
14. Mosesso P, Palitti F. The genetic toxicology of mercaptopurine. Mutat Res 1993; 296: 279-94.
15. Oakberg EF, Crosthwait CD, Raymer GD. Spermatogenic stage sensitivity to mercaptopurine in the mouse. Mutat Res 1982; 94: 165-78.
16. Russell LB, Hunsicker PR. Study of the base analog mercaptopurine in the mouse specific-locus test. Mutat Res 1987; 176: 47-52.
17. Generoso WM, Preston RJ, Brewen JG. 6-Mercaptopurine, an inducer of cytogenetic and dominant-lethal effects in premeiotic and early meiotic germ cells of male mice. Mutat Res 1975; 28: 437-47.
18. Friedman JM, Polifka JE. The Effects of Drugs on the Fetus and Nursing Infant. Baltimore: Johns Hopkins University Press. 1996.
19. Larsen H, Nielsen GL, Bendsen J, Flint C, Olsen J, Sorensen HT. Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries. Scand J Public Health 2003; 31: 12-6.
20. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998; 45: 320-3.
21. Mitchell AA. Special considerations in studies of drug-induced birth defects. In: Strom BL, ed. Pharmacoepidemiology, 3rd edn. Chichester: John Wiley & Sons, 2002: 749-63.
22. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 1103-12.